ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : CELL STRUCTURE
Scheme : Project Grants
Australian State/Territory : SA
Clear All
Filter by Field of Research
Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (1)
Clinical Sciences not elsewhere classified (1)
Immunogenetics (incl. Genetic Immunology) (1)
Molecular Targets (1)
Signal Transduction (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (5)
Filter by Status
Closed (5)
Filter by Scheme
Project Grants (5)
Filter by Country
Australia (5)
Filter by Australian State/Territory
SA (5)
  • Researchers (0)
  • Funded Activities (5)
  • Organisations (16)
  • Funded Activity

    Identification Of The Conformation Dependant Targets Of Autoimmune Disease Linked Variation In Human Regulatory T Cells

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,001,815.00
    Summary
    Specialised immune cells called regulatory T cells act as the policemen of the immune system, preventing the immune system attacking itself, but still fighting infections. If these cells do not work properly, autoimmune diseases such as type 1 diabetes or IBD can arise, because of immune attack on normal body tissue by mistake. In order to explain how this goes wrong we need to carefully identify all of the gene interactions in these cells including interactions over long distances in the DNA.
    More information
    Funded Activity

    Clinical Outcomes, Safety And Incremental Cost Effectiveness Of Multi-level Airway Surgery In Patients With Moderate-severe Obstructive Sleep Apnea (OSA) Who Have Failed Medical Management

    Funder
    National Health and Medical Research Council
    Funding Amount
    $652,794.00
    Summary
    Obstructive sleep apnoea (OSA) is a serious medical disorder with a high public health cost. OSA can be effectively treated but poor treatment compliance is a major clinical problem. As a consequence many OSA patients remain untreated, with significant implications for their long term health. New effective and safe therapies are needed. We believe that we will demonstrate a relatively straightforward, safe and effective surgical procedure for OSA after primary treatments fail. This will lead to .... Obstructive sleep apnoea (OSA) is a serious medical disorder with a high public health cost. OSA can be effectively treated but poor treatment compliance is a major clinical problem. As a consequence many OSA patients remain untreated, with significant implications for their long term health. New effective and safe therapies are needed. We believe that we will demonstrate a relatively straightforward, safe and effective surgical procedure for OSA after primary treatments fail. This will lead to improved patient outcomes.
    Read more Read less
    More information
    Funded Activity

    Understanding The Role Of The Atypical Cadherin Fat4 In Lymphatic Vascular Development

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,006,248.00
    Summary
    This application will define the role of a large cell adhesion molecule, FAT4, in lymphatic vascular development. By understanding how FAT4 functions in lymphatic vessels, we will gain insight to the mechanisms by which mutations in the gene that encodes this protein cause a human lymphoedema syndrome.
    More information
    Funded Activity

    Targeting MicroRNA-driven Mesenchymal To Epithelial Transition To Suppress Prostate Cancer Metastasis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $741,831.00
    Summary
    Prostate cancer kills ~3,000 men per year in Australia. The development of metastasis is the major cause of prostate cancer-associated death and has limited treatment options. In this study, we will characterise the role of a group of molecules, termed microRNAs, in prostate cancer metastasis. We will also test whether targeting microRNAs using novel drugs termed antagomiRs is an effective strategy to inhibit metastasis and thereby improve prostate cancer mortality.
    More information
    Funded Activity

    Mab Immunotherapies For Myeloid Leukemia Patients With Germline Or Somatic RUNX1 Mutations.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $766,995.00
    Summary
    This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.
    More information

    Showing 1-5 of 5 Funded Activites

    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback